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Galectins are potential biomarkers and therapeutic targets. However, galectins display broad affinity
towards b-galactosides meaning glycan-based (nano)biosensors lack the required selectivity and affinity.
Using a polymer-stabilized nanoparticle biosensing platform, we herein demonstrate that the specificity
of immobilised lacto-N-biose towards galectins can be ‘turned on/off’ by using site-specific glycan
fluorination and in some cases reversal of specificity can be achieved. The panel of fluoro-glycans were
obtained by a chemoenzymatic approach, exploiting BiGalK and BiGalHexNAcP enzymes from
Bifidobacterium infantis which are shown to tolerate fluorinated glycans, introducing structural diversity
which would be very laborious by chemical methods alone. These results demonstrate that integrating
non-natural, fluorinated glycans into nanomaterials can encode unprecedented selectivity with potential
applications in biosensing.Introduction
Galectins are a large group of soluble b-galactoside binding
proteins which are targets for therapy and diagnostics,
compared to other human lectin families which are typically
membrane-bound.1–3 Galectin-3 for example is overexpressed in
prostate cancers4 leading to endothelial cell adhesion,5 nano-
molar glycopeptide inhibitors of Galectin-3 have been shown to
suppress metastasis6 and several galectin-binders have
advanced to clinical trials.7 However, as all galectins bind
terminal b-galactosides to some extent, it is a signicant chal-
lenge to selectively target individual galectins.2 Percec and co-
workers have employed dendrimeric scaffolds to probe how
multivalent presentation of glycans affects galectin bindingrwick, CV4 7AL, UK. E-mail: m.i.gibson@
wick, CV4 7AL, UK
ck, CV4 7AL, UK
ork, Heslington, York, YO10 5DD, UK.
pton, Higheld, Southampton SO171BJ,
antock's Close, Bristol, BS8 1TS, UK
(ESI) available: This includes full
f glycans/nanoparticles and binding
of Chemistry 2020showing how topology and ligand density can be used to tune
affinity.8,9 Despite the promise of using glycans to detect ana-
lytes, antibody reagents remain the main clinical tools used in
ELISA,10 lateral ow11 or ow cytometry assays.
The installation of glycans onto polymer-coated gold nano-
particles is a powerful technology to probe lectin binding.12,13
The polymer coating provides steric stabilization to prevent
aggregation in complex media, and the incorporation of
multiple copies of a glycan at the polymer chain ends, increases
affinity due to the cluster glycoside effect.14 Gold nanoparticles
have unique optical properties,15,16 which enables signal
generation through aggregation13,17–19 in lateral ow devices,20,21
and also in surface enhanced Raman spectroscopy.22 However,
most studies with multivalent glycans involve mono/di-
saccharides which have shown limited selectivity so far.23
There is therefore a knowledge and technological gap, to
develop synthetically-accessible multivalent probes, which are
also endowed with selectivity.24
Fluorination of glycans inuences their physicochemical
properties and hence modulates their biological function.25–28
While uorine substitution has little effect on glycan confor-
mation,29,30 it can inuence hydrogen bonding properties of
adjacent hydroxyl groups,31,32 and uorine itself is a weak
hydrogen bond acceptor but not a hydrogen bond donor.33,34
Furthermore, uorine atoms can form attractive multipolar
interactions with proteins,35,36 and these have been observed
with uorinated carbohydrate derivatives,37 including galectinChem. Sci.
Fig. 1 (A) Chemical syntheses of fluorinated acceptors. (B) Fluorinated
lacto-N-biose analogues prepared using a chemoenzymatic strategy
with BiGalK and BiGalHexNAcP. TFA ¼ trifluoroacetyl.
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View Article Onlinebinders.38 Fluorinated sialyl oligosaccharides displayed signi-
cantly higher binding affinities for the Toxoplasma gondii lectin,
TgMIC1 in comparison to their non-uorinated counterparts.39
Similarly, uorinated MUC-1 antigens displayed enhanced
immunogenicity and differential binding affinity to mouse
antisera, making them useful tools for probing humoral
immune responses.40 Fluorinated glycans have also proven
effective for probing carbohydrate–lectin structure–activity
relationships. For example, Glca1–3ManaMe analogues uori-
nated around the Glc moiety revealed that the 2- and 3-OH
group of Glc were important for calreticulin binding, but not the
6-OH.41 Similarly, the 6-OH group of the a-1,6-branched
mannose in the Man3GlcNAc2 glycan, was shown to be
important for Concanavalin A binding.42
A powerful route to diversify unnatural glycans is to incor-
porate an enzymatic step. By using promiscuous enzymes for
glycosidic bond formation,27 which are capable of accepting
chemically accessible uorinated glycans, building blocks can
be combined, producing anomerically pure compounds, facili-
tating purication.
Herein we report a chemoenzymatic route to selectively
uorinated lacto-N-biose (Gal-b1–3-GlcNAc) glycans, including
uorination at both sugar residues, and their integration into
a multivalent glyconanoparticle platform. We demonstrate that
site-selective uorination enables modulation of the affinity
and introduces high selectivity towards Galectins 3 and 7 which
is not possible using native glycans. This approach demon-
strates the potential for the translation of glyconanomaterials to
applications in therapy and biosensing.
Results and discussion
Lacto-N-biose has conrmed affinity towards Galectin-3,43 so
a library of nine uorinated lacto-N-biose derivatives was syn-
thesised, using a modular chemoenzymatic approach (Fig. 1
and ESI†). Glycans were designed with an azido-propyl tether
for subsequent nanoparticle immobilization.17,44 This strategy
introduces diversity through the chemical uorination of the
individual monosaccharide building blocks, galactose (Gal) and
N-acetylglucosamine (GlcNAc), prior to enzymatic glycosylation
using a one-pot, two enzyme strategy. In this system, the kinase
BiGalK45 catalyses the formation of galactose-1-phosphates (Gal-
1Ps), before the phosphorylase BiGalHexNAcP46-catalyzed
transfer of Gal-1Ps to GlcNAc acceptors, by reverse phosphor-
ylysis.47 As several uorinated Gal derivatives are commercially
available, we focused on chemical diversication of the GlcNAc
acceptor. BiGalHexNAcP was previously shown to be highly
tolerant to modications at the 2- and 6-positions of GlcNAc
and GalNAc,46 so we focused our efforts on introducing uorine
to these positions (Fig. 1A). During a preliminary screen for
BiGalHexNAcP donor specicity, we found Gal (9), 3FGal (10)
and 6FGal (11) to be suitable donors, while little or no activity
was displayed towards 2FGal (12) and 4FGal (13) in the one-pot,
two enzyme system, when using GlcNAc-N3 (14) as the acceptor
(data not shown). Lacto-N-biose and uorinated derivatives
were efficiently synthesized on semi-preparative scale using
donors 9–11 and acceptors 5–8 & 14 (Fig. 1B and ESI†). ExcessChem. Sci.amounts of donor sugar (2–10 equiv.) were used to drive the
reactions towards disaccharide formation. For the less
preferred substrates (e.g. 3FGal), extended reaction times (up to
144 h) and the sequential addition of enzyme were used to
achieve maximum conversion. As high purity was required, all
glycans were subjected to a two-step purication (gel ltration
and ash or anion-exchange chromatography). In total, eight
uorinated disaccharides (16–23) bearing azidopropyl linkers
were prepared, in addition to lacto-N-biose derivative (15), in
isolated yields ranging from 25–76%.
PHEA (poly(hydroxylethyl acrylamide)) coated gold nano-
particles were selected for the screening, as these are an
established platform for glycan binding analysis.5,39 This tool
requires small (mg) quantities of glycans and hence is ideal for
screening compared to calorimetry or NMR-based approaches
which need more material, which is not always available. RAFTThis journal is © The Royal Society of Chemistry 2020
Fig. 3 Screening of lectin/F-GlycoNP binding. (A) Schematic of
aggregation assay; (B) dose–response to Soybean agglutinin (SBA); (C)
dose–response to Galectin-3; (D) aggregation kinetics with Galectin-
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View Article Online(reversible addition–fragmentation chain transfer) polymeriza-
tion was used to obtain telechelic PHEA ligands bearing a pen-
tauorophenyl (PFP) group at the a-terminus (Fig. 2A).44,48 The
PFP was displaced by dibenzocyclooctyne-amine, introducing
a handle (validated by 19F NMR) to capture the glycosyl azide, by
strain promoted azide/alkyne click (SPAAC). By using RAFT, an
u-terminal thiol was also produced enabling assembly of the
glycoligands onto 55 nm gold nanoparticles with excess poly-
mer removed by centrifugation/resuspension cycles. The
nanoparticle size and polymer chain length (DP25) used were
guided by previous work, to give a balance between colloidal
stability and aggregation responses.39 UV-visible spectroscopy
showed the characteristic SPR band (533 nm) and no aggrega-
tion (at 700 nm) aer polymer coating (Fig. 2B). Dynamic light
scattering showed a small increase in hydrodynamic diameter
consistent with polymer coating (Fig. 2C). X-ray photoelectron
spectroscopy (XPS, in ESI†) conrmed the presence of the
polymers and the uorine from the glycans.
With this panel of uoro-glycan nanoparticles (GlycoAuNPs)
in hand, their lectin binding affinity/selectively trends could be
evaluated, initially using soybean agglutinin (SBA) which pref-
erentially binds b-D-galactosides.13,49 Binding was assessed by
exploiting the optical properties of the GlycoAuNPs, whereby
SBA binding leads to aggregation of the nanoparticles (Fig. 3A).
This results in a red-blue colour shi which can be assessed by
UV-visible spectroscopy (Fig. 3B).17,18,50 As expected, lacto-N-
biose (15) showed weak affinity towards SBA (KD, apparent > 10
mM; KD values for multivalent systems are very challenging toFig. 2 Nanoparticle synthesis and characterization. (A) Synthetic route
to conjugate fluoro-glycans onto nanoparticles; (B) UV-Vis traces of all
nanoparticles showing colloidal stability; (C) dynamic light scattering
(DLS) of all nanoparticles showing size increase upon polymer coating.
3; (E) dynamic light scattering with Galectin-3.
This journal is © The Royal Society of Chemistry 2020determine). Fluorine addition to the GlcNAc unit improved the
binding >12-fold, where Gal-b(1,3)-6FGlcNTFA (20, dark blue
line), Gal-b(1,3)-6,6diFGlcNAc (22, pink line) and Gal-b(1,3)-
6,6diFGlcNTFA (23, green line) all show KD,apparent values in
the range of 0.84–0.89 mM. Furthermore Gal-b(1,3)-6FGlcNAc
(18, dark purple line) does not have sufficient uorine incor-
poration to see this increase in binding. Fluorination in any
position around the galactose ring was not tolerated, resulting
in decreased binding affinity in the cases of 6FGal-b(1,3)-
6FGlcNTFA (21) compared to Gal-b(1,3)-6FGlcNTFA (20).
Guided by these experiments with SBA, Galectin-3 binding
was proled (Fig. 3C). Galectin-3 has only a single binding site,
but is in equilibrium with a pentameric form, and hence can
cross-link multivalent glycomaterials.51 Lacto-N-biose (15)
particles bound Galectin-3, agreeing with previous observations
from Hsieh et al.43 However, a number of uorinated lacto-N-
biose derivatives bound with a greater affinity to Galectin-3 than
native (15), with 3FGal-b(1,3)-GlcNAc (16), Gal-b(1,3)-
6,6diFGlcNTFA (23), Gal-b(1,3)-6FGlcNTFA (20) and Gal-b1(1,3)-
6,6diFGlcNAc (22) all showing enhanced binding. In contrast,
any glycan with a 6FGal derivative, such as 6FGal-b(1,3)-GlcNAc
(17), 6FGal-b(1,3)-6FGlcNAc (19) and 6FGal-b(1,3)-6FGlcNTFA
(21) completely ‘switched off’ the binding to Galectin-3. Kinetic
analysis of aggregation agreed with dose–response (Fig. 3D)
data, with 3FGal-b(1,3)-GlcNAc (16) showing the fastest rate.
This was conrmed by dynamic light scattering (Fig. 3E)Chem. Sci.
Chemical Science Edge Article
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View Article Onlineshowing that ‘non-binder’ 6FGal-b(1,3)-6FGlcNTFA (21) does
not lead to aggregation. This provides strong evidence that
subtle site-specic uorination is a powerful tool to introduce
affinity and selectivity into glycans against biomedically rele-
vant lectins, when conjugated to nanoparticles.
To further validate the aggregation-based assays, biolayer
interferometry (BLI) was employed.12 Galectin-3 was bio-
tinylated, then immobilized onto streptavidin-functional BLI
sensors, and the GlycoAuNPs applied (Fig. 4). Lacto-N-biose (15,
Fig. 4A) showed little binding due to the concentrations used (to
enable enhancements to be observed without saturation). In
agreement with the aggregation-based assays, signicant
binding was observed using 3FGal-b(1,3)-GlcNAc (16, Fig. 4B),
and there was some limited binding observed with Gal-b(1,3)-
6FGlcNTFA (20, Fig. 4C). Also in line with the aggregation data,
no binding was seen for 6FGalb(1,3)-6FGlcNTFA (21, Fig. 4D).
Indeed, consideration of the crystal structure (PDB entry
4XBN43) of Galectin-3 with lacto-N-biose reveals an interaction
of the 6-OH of galactose with residues Asn174A/Glu184A, sup-
porting our observation that 6-OH replacement with uorine is
detrimental for binding. The 3-OH group is not involved in H-
bonding interactions and hence uorination does not
diminish binding, and instead appears to increase the overall
affinity. Overall, these data conclusively show that site-specic
uorination enables precise modulation of binding affinity
and could be used to generate nanoparticle biosensors for rapid
detection of this important biomarker.
Encouraged by the Galectin-3 binding data, the utility of
these unique uoro-glycan nanoparticles to discriminate
between individual galectins was explored, which is oen not
possible with natural glycans nor with monosaccharide-based
glycomaterials. Galectin-7 was chosen as it has previously
been reported to have lower affinity towards lacto-N-biose (270
mM) than Galectin-3 (93 mM)43 and hence offers a robust chal-
lenge to explore how uorination can be used to tuneFig. 4 Biolayer interferometry analysis of binding of AuNPs to
Galectin-3. (A) Lacto-N-biose (15); (B) 3FGal-b(1,3)-GlcNAc (16); (C)
Gal-b(1,3)-6FGlcNTFA (20); (D) 6FGal-b(1,3)-6FGlcNTFA (21).
Chem. Sci.specicity/affinity. Binding of Galectin-7 to the library of parti-
cles by the aggregation assay (as described above) was con-
ducted, and Fig. 5 shows the relative affinities as KD,apparent.
Lacto-N-biose particles showed preference for Galectin 3 as
anticipated, displaying limited binding to Galectin-7 in the
concentration range tested. Introduction of uorine atoms
resulted in a variation of the observed KD's, but in particular
6FGalb(1,3)-6FGlcNTFA (21) showed switching of affinity
compared to non-uorinated ligands: this derivative showed no
affinity to Galectin-3, but the uorination results in ‘switching
on’ of affinity towards Galectin-7. The extent of aggregation at
plateau for 21 was lower than for 15, but clear binding was seen.
It is important to highlight that these assays cannot identify if
glycans engage the protein in the same manner, or at different
(non-canonical) binding sites. This affinity switch shows that
the site-specic incorporation of uorine atoms can overcome
the low selectivity of glycans towards their lectin partners and in
some cases completely turn off interactions. Additional glycan
modications to a core lactosyl unit in a glycan array have also
been reported to modulate galectin binding patterns, which is
complementary to the approach taken here.52 Such selectivity is
essential in the development of glyconano tools for therapy and
diagnostics. Furthermore, this chemoenzymatic synthetic
approach to glycan libraries may facilitate screening of binding
epitopes by methods such as (STD) NMR53–55 which require
more material and have lower throughput.Experimental
Full experimental details are in the electronic ESI.† This
includes characterization of all glycans and nanomaterials.Fig. 5 Galectin-7 binding to the F-glyconanoparticle library. (A)
Dose–response curve for the AuNP aggregation assay; (B) summary of
apparent KD (nM) for selected glycans showing the fine-tuning and
selectivity inversion. () ¼ no binding.
This journal is © The Royal Society of Chemistry 2020
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View Article OnlineConclusions
To conclude, a chemoenzymatic glycosylation strategy was
employed for the rapid assembly of a diverse library of (multi)
uorinated lacto-N-biose derivatives, which were integrated into
nanobiosensors. The efficient one-pot enzymatic glycosylation
process connes the protecting group requirements to the
chemical synthesis of the uorinated acceptors, and reveals
a large substrate tolerance of the BiGalK and BiGalHexNAcP
enzymes. These uoro-glycans were conjugated to polymer-
stabilized gold nanoparticles, which were used to reveal
unique binding patterns and signicant enhancements in
selectivity towards two Galectins. Due to the use of nano-
particles, only very low amounts (mg) of glycan per assay are
required in contrast to other methods. It was discovered that
a single uorine at 3-position of the galactose residue dramat-
ically enhanced binding towards Galectin-3. Fluorine at other
locations dramatically reduced binding, with 6-uorination
abrogating all binding affinity. Galectin-7 was also screened
which does not normally show any signicant binding to the
native lacto-N-biose. It was shown that selective uorination
allowed complete reversal of selectivity such that a penta-
uorinated derivative only bound Galectin-7 and all binding to
Galectin-3 was removed, which is an unprecedented switch in
selectivity. This is notable as glycans normally display a range of
binding affinities but here uorination enables the introduc-
tion of binary on/off responses which may be useful in the
design of biosensors, and innovative diagnostics. These nd-
ings show that subtle uorination strategies can engineer
marked selectivity into immobilized glycans. This will aid the
development of new sensing platforms which are not accessible
using native mono/disaccharides due to their broad binding
affinities, and the development of glycan-diagnostics as alter-
natives to traditional antibody-based techniques.Conflicts of interest
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